Drugs / Thiotepa
last change 3 days ago re-read 2 minutes ago

Thiotepa

Other / unclassified

Developed for
myelodysplastic syndrome · breast cancer · neuroblastoma · acute myeloid leukemia · lymphoma · leukemia · primary central nervous system lymphoma · central nervous system neoplasm
+128 more · acute lymphoblastic leukemia · chronic myeloid leukemia · plasma cell myeloma · chronic lymphocytic leukemia/small lymphocytic lymphoma · Hodgkins lymphoma · medulloblastoma · ovarian cancer · central nervous system non-hodgkin lymphoma · childhood germ cell tumor · retinoblastoma · sarcoma · atypical teratoid rhabdoid tumor · brain cancer · childhood malignant neoplasm · non-Hodgkin lymphoma · testicular germ cell tumor · brain neoplasm · cancer of unknown primary site · central nervous system cancer · extragonadal germ cell tumor · immunodeficiency disease · lymphoblastic lymphoma · myelofibrosis · neoplastic meningitis · acute biphenotypic leukemia · bone marrow failure syndrome · Burkitt lymphoma · CD4+/CD56+ hematodermic neoplasm · chronic granulomatous disease · chronic myelomonocytic leukemia · common variable immunodeficiency · diffuse large B-cell lymphoma · female breast carcinoma · hemophagocytic syndrome · Hurler syndrome · mantle cell lymphoma · paroxysmal nocturnal hemoglobinuria · pineoblastoma · primitive neuroectodermal tumor · severe combined immunodeficiency · sickle cell disease · supratentorial primitive neuroectodermal tumor · thalassemia · Wiskott-Aldrich syndrome · X-linked lymphoproliferative syndrome · acquired thrombocytopenia · acute leukemia · adrenoleukodystrophy · aggressive B-cell non-Hodgkin lymphoma · anaplastic ependymoma · anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · autoimmune lymphoproliferative syndrome · B-cell acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · benign neoplasm · beta thalassemia · brain glioblastoma · breast carcinoma · Bruton-type agammaglobulinemia · central nervous system germ cell tumor · central nervous system leukemia · cerebral primitive neuroectodermal tumor · Chediak-Higashi syndrome · childhood medulloblastoma · choriocarcinoma · choroid plexus carcinoma · Diamond-Blackfan anemia · DiGeorge syndrome · embryonal carcinoma · embryonal tumor with multilayered rosettes · ependymoblastoma · Ewing sarcoma · Ewing sarcoma/peripheral primitive neuroectodermal tumor · extraocular retinoblastoma · follicular lymphoma · head and neck cancer · hematologic disorder · hemolytic anemia · hepatoblastoma · histiocytosis · hyper-IgM syndrome · IDH-wildtype glioblastoma · immune dysregulation, autoimmunity, and autoinflammation · immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome · inborn errors of metabolism · inflammatory breast carcinoma · invasive breast carcinoma · juvenile myelomonocytic leukemia · kidney cancer · kidney neoplasm · liver cancer · lymphoid hemopathy · lymphoplasmacytic lymphoma · lymphoproliferative syndrome · malignant leptomeningeal tumor · marginal zone lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloblastoma SHH activated and TP53 wild-type · medulloepithelioma · metastatic neoplasm · mixed germ cell tumor · mixed phenotype acute leukemia · myelodysplastic/myeloproliferative disease · myelodysplastic/myeloproliferative neoplasm · myeloid leukemia · myeloid sarcoma · myeloproliferative neoplasm · neutropenia · oligosaccharidosis · osteosarcoma · ovarian carcinoma · Philadelphia-positive myelogenous leukemia · pineal region immature teratoma · pineal region yolk sac tumor · primary brain neoplasm · prolymphocytic leukemia · rhabdomyosarcoma · soft tissue sarcoma · systemic sclerosis · T lymphoblastic leukemia/lymphoma · T-cell non-Hodgkin lymphoma · teratoma · urinary bladder cancer · urothelial carcinoma · hematopoietic and lymphoid cell neoplasm
Investigated by
National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · Memorial Sloan Kettering Cancer Center · Children's Oncology Group · M.D. Anderson Cancer Center · Washington University School of Medicine
+120 more · Gustave Roussy, Cancer Campus, Grand Paris · Masonic Cancer Center, University of Minnesota · Second Affiliated Hospital, School of Medicine, Zhejiang University · Herbert Irving Comprehensive Cancer Center · NYU Langone Health · Roswell Park Cancer Institute · Samsung Medical Center · The First Affiliated Hospital with Nanjing Medical University · The Netherlands Cancer Institute · University Hospital Freiburg · University Hospital Tuebingen · Zhejiang Cancer Hospital · Assistance Publique - Hôpitaux de Paris · Association for Training, Education, and Research in Hematology, Immunology, and Transplantation · Children's Cancer and Leukaemia Group · Children's Hospital Los Angeles · Children's of Alabama · First Affiliated Hospital Xi'an Jiaotong University · German Federal Ministry of Education and Research · Hackensack Meridian Health · Institut Curie · Klinikum Stuttgart · National Heart, Lung, and Blood Institute (NHLBI) · Northwestern University · Peking University People's Hospital · Ruijin Hospital · Scottish Cancer Therapy Network · Seoul National University Hospital · Sheba Medical Center · The Affiliated Brain Hospital of Nanjing Medical University · UNICANCER · ALL SCTped Forum · ALL-BFM Study Group · Adienne SA · Alliance for Clinical Trials in Oncology · Amgen · Andrés José Maria Ferreri · Australian & New Zealand Children's Haematology/Oncology Group · Baptist Health South Florida · Barbara Ann Karmanos Cancer Institute · Beijing Friendship Hospital · C17 Council · Cancer and Leukemia Group B · Carelon Research · Case Comprehensive Cancer Center · Centre Leon Berard · Charite University, Berlin, Germany · Children's Discovery Institute · Children's Hospitals and Clinics of Minnesota · City of Hope Medical Center · Columbia University · Dutch Childhood Oncology Group · Eastern Cooperative Oncology Group · European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · European Society for Blood and Marrow Transplantation · FengYan Jin · First Affiliated Hospital of Zhejiang University · Fudan University · GWT-TUD GmbH · Georgetown University · German Society of Paediatric Oncology and Hematology (GPOH gGmbH) · Guangdong 999 Brain Hospital · Guenther Koehne · H. Lee Moffitt Cancer Center and Research Institute · Heinrich-Heine University, Duesseldorf · Hoffmann-La Roche · Huiqiang Huang · International Extranodal Lymphoma Study Group (IELSG) · Italian Group for Bone Marrow Transplantation · Jazz Pharmaceuticals · Jun Zhu · King's College Hospital NHS Trust · Live Like Bella Pediatric Cancer Research · Louisiana State University Health Sciences Center Shreveport · all 126 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Tepadina 2010-03-15 europa.eu
Approved US (FDA) THIOTEPA 1959-03-09 fda.gov

Trials 163 · started per year

today
US approved 1959
EU approved 2010
1
1
1
3
3
3
9
6
6
4
5
4
1
5
4
5
8
4
10
4
4
2
2
3
6
3
2
7
3
1
8
9
2
7
10
7
195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06942039 Sep 2025 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 C17 Council Recruiting No outcome recorded
Phase 111 trials
Phase 1 NCT06195891 May 2024 → Mar 2030 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT05088356 Sep 2021 → May 2028 expected acute leukemia, chronic myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Stanford University Active not recruiting No outcome recorded
Phase 1 NCT04521946 Jan 2021 → Dec 2022 anaplastic ependymoma, atypical teratoid rhabdoid tumor, central nervous system germ cell tumor, choroid plexus carcinoma +3 M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT02660281 Oct 2015 → Oct 2019 immunodeficiency disease, myelofibrosis, plasma cell myeloma University of Rochester Completed No outcome recorded
Phase 1 NCT00972101 Sep 2009 → Sep 2011 disease related to hematopoietic stem cell transplant, leukemia, lymphoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT00867178 Feb 2009 → Apr 2020 medulloblastoma, pineoblastoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00003899 Jan 1999 → Nov 2001 cancer of unknown primary site Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1 NCT00003081 Mar 1998 → Jan 2002 sarcoma Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1 NCT00003141 Mar 1998 → Dec 2007 brain cancer, neuroblastoma, sarcoma Children's Oncology Group Completed No outcome recorded
Phase 1 NCT00002977 Jan 1997 → Nov 2001 ovarian cancer Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT06158828 Nov 2024 → Sep 2028 expected acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia Washington University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT05021770 Dec 2021 → Dec 2022 non-Hodgkin lymphoma, primary central nervous system lymphoma Huiqiang Huang Unknown No outcome recorded
Phase 1/2 NCT03513328 Jun 2018 → Feb 2022 Diamond-Blackfan anemia, Hurler syndrome, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome +12 University of Florida Completed No outcome recorded
Phase 1/2 NCT00801931 Sep 2007 → May 2009 anemia, immunodeficiency disease, leukemia, lymphoma +1 Columbia University Terminated No outcome recorded
Phase 1/2 NCT00112567 Apr 2003 → Jul 2007 leukemia, myelodysplastic syndrome Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00920972 Dec 2001 → Dec 2026 expected inherited hemoglobinopathy, metabolic disease Washington University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT00003297 Dec 1997 → Jan 2001 ovarian cancer Georgetown University Completed No outcome recorded
Phase 1/2 NCT00003086 Mar 1997 → Jan 2001 female breast carcinoma Louisiana State University Health Sciences Center Shreveport Terminated No outcome recorded
Phase 2102 trials
Phase 2 NCT05565105 Jun 2026 → Jun 2033 expected acute lymphoblastic leukemia, acute myeloid leukemia Guenther Koehne Not yet recruiting No outcome recorded
Phase 2 NCT07604987 May 2026 → May 2028 expected primary central nervous system lymphoma Zou Dehui Recruiting No outcome recorded
Phase 2 NCT07481669 Mar 2026 → Mar 2028 expected lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2 NCT07416890 Feb 2026 → Aug 2028 expected central nervous system non-hodgkin lymphoma Zhejiang Cancer Hospital Recruiting No outcome recorded
Phase 2 NCT07511725 Jan 2026 → Jan 2028 expected IDH-wildtype glioblastoma Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2 NCT07276737 Dec 2025 → Dec 2029 expected mature T-cell and NK-cell non-Hodgkin lymphoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 2 NCT07263425 Oct 2025 → Oct 2027 expected neoplastic meningitis The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT06869265 May 2025 → Apr 2028 expected acute myeloid leukemia Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT07193654 Apr 2025 → Apr 2027 expected brain glioblastoma Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06901999 Apr 2025 → Nov 2026 expected central nervous system non-hodgkin lymphoma Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2/36 trials
Phase 2/3 NCT04217278 Jan 2020 → May 2026 overdue acute myeloid leukemia, myelodysplastic syndrome University of Birmingham Active not recruiting No outcome recorded
Phase 2/3 NCT01949129 Apr 2013 → Jun 2025 overdue acute lymphoblastic leukemia St. Anna Children's Cancer Research Recruiting No outcome recorded
Phase 2/3 NCT01057069 Jan 2010 → Jun 2023 overdue breast cancer The Netherlands Cancer Institute Active not recruiting No outcome recorded
Phase 2/3 NCT00448266 May 2007 → Feb 2010 breast cancer The Netherlands Cancer Institute Terminated No outcome recorded
Phase 2/3 NCT00749723 Feb 2006 → Jan 2015 ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumor University Hospital, Bonn Completed No outcome recorded
Phase 2/3 NCT00003816 Oct 1998 → Jul 2019 benign neoplasm, childhood malignant neoplasm, leukemia, lymphoma +3 Roswell Park Cancer Institute Completed No outcome recorded
Phase 318 trials
Phase 3 NCT07291102 Jul 2026 → Oct 2034 expected medulloblastoma SHH activated and TP53 wild-type Nationwide Children's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06830421 Aug 2023 → Aug 2029 expected primary central nervous system lymphoma University Hospital Freiburg Recruiting No outcome recorded
Phase 3 NCT04931368 Jun 2021 → Jun 2028 expected primary central nervous system lymphoma Klinikum Stuttgart Active not recruiting No outcome recorded
Phase 3 NCT04221035 Nov 2019 → Nov 2026 expected neuroblastoma Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 3 NCT01646034 Sep 2014 → Jan 2023 overdue breast cancer The Netherlands Cancer Institute Active not recruiting No outcome recorded
Phase 3 NCT01091168 Jul 2009 → Aug 2012 breast cancer, metastatic neoplasm Pierre Fabre Laboratories Completed No outcome recorded
Phase 3 NCT00653068 Feb 2009 → Sep 2016 atypical teratoid rhabdoid tumor Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00554788 May 2008 → Jun 2018 extraocular retinoblastoma Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00567567 Nov 2007 → Feb 2015 neuroblastoma Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00078988 Oct 2004 → Sep 2006 brain neoplasm Children's Oncology Group Completed No outcome recorded
Phase 42 trials
Phase 4 NCT06230055 Jan 2024 → Jan 2026 overdue Her2-receptor negative breast cancer, malignant leptomeningeal tumor Fudan University Recruiting No outcome recorded
Phase 4 NCT02875314 Sep 2015 → Dec 2030 expected central nervous system cancer, medulloblastoma Parth Patel Active not recruiting No outcome recorded
Phase not applicable15 trials
NCT07588594 Feb 2026 → May 2028 expected chronic myelomonocytic leukemia Peking University People's Hospital Recruiting No outcome recorded
NCT07191431 Sep 2025 → Sep 2027 expected central nervous system non-hodgkin lymphoma Ruijin Hospital Recruiting No outcome recorded
NCT06832267 Feb 2025 → Feb 2027 expected primary central nervous system lymphoma Zhejiang Cancer Hospital Recruiting No outcome recorded
NCT06385808 May 2024 → Dec 2026 expected acute myeloid leukemia First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
NCT05667402 Jan 2023 → Dec 2025 central nervous system leukemia, disease related to hematopoietic stem cell transplant First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
NCT06946407 Dec 2022 → Dec 2027 expected central nervous system non-hodgkin lymphoma FengYan Jin Recruiting No outcome recorded
NCT05854225 Jan 2022 → Jun 2024 hemophagocytic syndrome Beijing Friendship Hospital Unknown No outcome recorded
NCT03035422 Jan 2018 → Dec 2021 acute myeloid leukemia Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
NCT03079089 Jun 2017 → Sep 2023 lymphoid hemopathy Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
NCT01505569 Oct 2011 → Feb 2024 Ewing sarcoma, atypical teratoid rhabdoid tumor, germ cell tumor, hepatoblastoma +6 Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Also used as a comparator or background therapy in 131 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT02653196 Background Sep 2015 → Aug 2017 neuroepithelial neoplasm Montefiore Medical Center Terminated No outcome recorded
Phase 0 NCT00790413 Background Aug 2005 → Dec 2022 neuroblastoma Lund University Hospital Unknown No outcome recorded
Phase 124 trials
Phase 1 NCT07257419 Background Aug 2026 → Dec 2031 expected childhood acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT07565220 Background Aug 2026 → Jun 2029 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Sawa Ito, MD Recruiting No outcome recorded
Phase 1 NCT07052370 Background Sep 2025 → Dec 2028 expected hematopoietic and lymphoid system neoplasm St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT06900192 Background Mar 2025 → Aug 2029 expected primary progressive multiple sclerosis, secondary progressive multiple sclerosis Stanford University Not yet recruiting No outcome recorded
Phase 1 NCT06193759 Background Sep 2024 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood central nervous system primitive neuroectodermal neoplasm, childhood medulloblastoma, embryonal tumor with multilayered rosettes +2 Children's National Research Institute Recruiting No outcome recorded
Phase 1/220 trials
Phase 1/2 NCT07372885 Background Feb 2026 → Dec 2028 expected acute myeloid leukemia University of Manchester Not yet recruiting No outcome recorded
Phase 1/2 NCT03597594 Comparator Sep 2021 → Jul 2027 expected severe combined immunodeficiency St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT03653338 Background Aug 2018 → Aug 2026 overdue Diamond-Blackfan anemia, beta-thalassemia major, sickle cell disease Paul Szabolcs Recruiting No outcome recorded
Phase 1/2 NCT03500731 Background Apr 2018 → Dec 2027 expected chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis Paul Szabolcs Recruiting No outcome recorded
Phase 1/2 NCT02724904 Background May 2017 → Dec 2019 lymphoma Massachusetts General Hospital Withdrawn No outcome recorded
Phase 266 trials
Phase 2 NCT07616154 Background Sep 2026 → Sep 2034 expected sickle cell disease St. Jude Children's Research Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07677813 Background Jun 2026 → Dec 2029 expected MCD diffuse large B-cell lymphoma Ou Bai, MD/PHD Not yet recruiting No outcome recorded
Phase 2 NCT07562568 Background Jun 2026 → Jun 2030 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 2 NCT07566377 Background Apr 2026 → Apr 2030 expected Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, graft versus host disease +1 Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT07441967 Background Feb 2026 → Dec 2027 expected hematopoietic and lymphoid system neoplasm Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT04708054 Background Oct 2021 → Dec 2027 expected acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2/3 NCT02707393 Background Apr 2009 → Dec 2020 chronic myeloid leukemia St. Anna Children's Cancer Research Completed No outcome recorded
Phase 312 trials
Phase 3 NCT06172296 Background Apr 2024 → Dec 2029 expected neuroblastoma, nodular ganglioneuroblastoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 3 NCT05457556 Background Mar 2023 → Jun 2026 overdue acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome Children's Oncology Group Active not recruiting No outcome recorded
Phase 3 NCT03126916 Background May 2018 → Sep 2030 expected neuroblastoma, nodular ganglioneuroblastoma Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT02810743 Comparator Jan 2017 → Jul 2024 overdue breast cancer The Netherlands Cancer Institute Active not recruiting No outcome recorded
Phase 3 NCT02531841 Comparator Jul 2014 → Nov 2017 diffuse large B-cell lymphoma University Hospital Freiburg Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT00003398 Background Sep 1998 → May 2000 anemia, graft versus host disease, leukemia, myelodysplastic syndrome +1 University of Maryland, Baltimore Completed No outcome recorded
Phase not applicable4 trials
NCT07563920 Background Jun 2026 → Jun 2029 expected acute myeloid leukemia Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
NCT02880293 Background Aug 2016 → Nov 2023 hematopoietic and lymphoid cell neoplasm Memorial Sloan Kettering Cancer Center Completed No outcome recorded
NCT01598025 Background May 2012 → Oct 2017 acute leukemia, chronic leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma Memorial Sloan Kettering Cancer Center Terminated No outcome recorded
NCT00145587 Background Jul 2004 → Feb 2009 osteopetrosis St. Jude Children's Research Hospital Terminated No outcome recorded

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 295 sources stand behind the page.

FieldValueCited text
Known as thiotepa “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244
292

“Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626

“Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189

“Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea,...” PMID 24296492 Dec 2013

“Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an...” NCT00145587

“Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted...” NCT00143559

“Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 +...” NCT04103879

“Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113

“MATRix Regimen: Rituximab 375 mg/m² IV on Day 0; Methotrexate 3.5 g/m² IV on Day 1; Cytarabine 2 g/m² IV twice daily on Days 2-3; Thiotepa 30 mg/m² orally on Day 4.” NCT07350850

“Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823

“Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan.” NCT00145613

“Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1.” NCT01049854

“Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG.” NCT00152139

“3000 mg/m2 cyclophosphamide on day 1, 250 mg/m2 thiotepa on day 2, and 400 mg/m2 carboplatin intravenously on days 1 and 2” PMID 42372741 Jul 2026

“high-dose rituximab combined with thiotepa, busulfan, and cyclophosphamide (R-TBC) for ASCT was conducted.” PMID 25204639 Sep 2014

“carboplatin and thiotepa, each followed by an infusion of autologous peripheral blood stem cells (PBSCs)” NCT06193759

“Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.” NCT04931368

“Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545

“The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.” NCT05667402

“Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816

“standardised conditioning regimen involving Fludarabine, Cyclophosphamide, Thiotepa, and TBI” NCT07372885

“The three drugs to be used in this research study are thiotepa, etoposide and carboplatin.” NCT02875314

“Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine” NCT04761770

“cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168

“cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy” NCT03913026

“High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin” NCT00851110

“Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.” NCT03509961

Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent” NCT02626715

“high-dose Thiotepa-BCNU supported by autologous stem cell transplant” NCT00801216

thiotepa (T, 30 mg/m²) is administered intravenously on day 1” NCT07604987

“Myeloablative regimen of busulfan, fludarabine, and thiotepa.” NCT06900192

Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6)” NCT01342237

“Intravenous thiotepa 5 mg/kg/d on days -11,-10” NCT07588594

Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7” NCT00863460

“fludarabine, thiotepa ,cyclophosphamide (FTC)” NCT04121507

Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4)” NCT05884333

Thiotepa 5 mg / kg / day for 1 day (D-13)” NCT03035422

thiotepa (5mg/kg/d) on days -8 and -7” NCT01220544

Thiotepa 5 mg/kg/day for 1 day (D-13)” NCT03079089

Thiotepa 5 mg/kg/d i.v. d-5 and d-4” NCT06830421

thiotepa 5 mg/kg on days -8 and -7” NCT07562568

“Thioguanine, Thiotepa, Topotecan” NCT02788201

“Carboplatin, thiotepa, etoposide” NCT07291102

“adding thiotepa and reducing CYC” NCT01895244

thiotepa 40 mg/m(2) i.v. Day 2” PMID 23242601 Dec 2012

thiotepa (10 mg/kg IV) day -8” NCT01461837

Thiotepa 30 mg/m² i.v. (d4)” NCT02531841

thiotepa 5mg/kg IV x 2 days” NCT00587054

“Day -4: Thiotepa 8mg/kg IV” NCT00920972

“Day -4: Thiotepa 8mg/kg IV” NCT01005576

Thiotepa 30 mg/m² Day 4” NCT07677813

thiotepa(10mg, q1-3w)” NCT06230055

thiotepa (8mg/kg IV)” NCT03128996

Thiotepa Day -4” NCT02165007

“* ThiotepaNCT02171104

ThiotepaNCT06385808

NCT00357396

NCT04151706

NCT02790515

NCT06901999

NCT00867178

NCT03399773

NCT04362293

NCT07565220

NCT00002616

NCT00429182

NCT07416890

NCT00020722

NCT00376480

NCT07616154

NCT00002680

NCT02259348

NCT02049580

NCT00432094

NCT00002704

NCT00025558

NCT07259161

NCT03126916

NCT05303727

NCT00006123

NCT01010217

NCT00857389

NCT00002718

NCT00692939

NCT00005798

NCT02784015

NCT04530487

NCT03630211

NCT00003972

NCT00317408

NCT02025881

NCT02784054

NCT07263425

NCT07441967

NCT00003926

NCT06543992

NCT02061800

NCT00003899

NCT00313521

NCT00002755

NCT00005092

NCT00801931

NCT00047320

NCT00916045

NCT00002772

NCT00002780

NCT05457556

NCT01746849

NCT03980769

NCT00749723

NCT00739141

NCT00423514

NCT06807606

NCT00202917

NCT06376292

NCT00647049

NCT00101140

NCT04521946

NCT05579769

NCT04217278

NCT00978471

NCT00112567

NCT06832267

NCT03263559

NCT00462787

NCT00004906

NCT00025324

NCT07493486

NCT02867800

NCT00004900

NCT00012311

NCT04872595

NCT07052370

NCT00536601

NCT07276737

NCT03615105

NCT06252870

NCT00182793

NCT00002836

NCT01350258

NCT02870907

NCT02724904

NCT00180791

NCT03849651

NCT00027937

NCT03615144

NCT00045539

NCT06468267

NCT06013423

NCT07257419

NCT00002870

NCT00238433

NCT00003852

NCT00336024

NCT00936156

NCT01423747

NCT06646211

NCT06869265

NCT03342196

NCT00623077

NCT04083170

NCT01505569

NCT01511562

NCT07014943

NCT06625359

NCT00003846

NCT06158828

NCT06687772

NCT00303810

NCT01598025

NCT01025778

NCT00028730

NCT00002977

NCT00295971

NCT01646034

NCT06946407

NCT01050764

NCT04859946

NCT00104975

NCT00003816

NCT04282174

NCT01119066

NCT00382109

NCT02220985

NCT02757885

NCT07193654

NCT00017368

NCT02199041

NCT02329080

NCT01423500

NCT04684368

NCT03434704

NCT02861417

NCT02507479

NCT00002534

NCT00653068

NCT03513328

NCT00003064

NCT04678401

NCT00914940

NCT06942039

NCT06172296

NCT00972101

NCT04221035

NCT00528437

NCT00003068

NCT03885947

NCT01814475

NCT00003680

NCT02660281

NCT00392886

NCT00567567

NCT00003080

NCT00008203

NCT00824135

NCT00066417

NCT00943800

NCT00003081

NCT00003086

NCT00025077

NCT05598593

NCT00040872

NCT07191431

NCT00002515

NCT00593554

NCT03061656

NCT01858740

NCT02880293

NCT00793845

NCT05565105

NCT00003101

NCT03779854

NCT00008008

NCT00961142

NCT00003146

NCT00004174

NCT05021770

NCT00621036

NCT00790413

NCT02605421

NCT01690520

NCT00003173

NCT05931328

NCT06060782

NCT00038857

NCT03653338

NCT02653196

NCT00607984

NCT00067002

NCT01786018

NCT00078988

NCT00007982

NCT04708054

NCT01807611

NCT00003199

NCT00719888

NCT00003398

NCT07566377

NCT01949129

NCT00392782

NCT00448266

NCT03346096

NCT07563920

NCT00003141

NCT01962415

NCT00588523

NCT00450983

NCT00004172

NCT03970096

NCT01011920

NCT05088356

NCT02333838

NCT00002471

NCT00160355

NCT00003273

NCT01821781

NCT03597594

NCT06195891

NCT00060255

NCT07481669

NCT00002619

NCT03500731

NCT02707393

NCT00003297

NCT00003877

NCT03165292

NCT06680661

NCT00004092

NCT07511725

NCT01810926

NCT05854225

NCT00554788

NCT01057069

Known as 1,1',1''-Phosphinothioylidynetrisaziridine 1,1',1''-PhosphinothioylidynetrisaziridineNCT02220985
Known as Girostan GirostanNCT02220985
Known as NSC-6396 “Thiotepa, TSPA, NSC-6396NCT00002471
1

“TSPA Thiotepa, NSC-6396NCT00002704

Known as Tepadina ChEMBL registry synonym — accepted as the source's own label CHEMBL671
Known as Tepylute ChEMBL registry synonym — accepted as the source's own label CHEMBL671
Known as Tespamin TespaminNCT02220985
Known as THIO Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)” NCT06680661
1

Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4)” NCT05884333

Known as Thioplex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00566696
Known as Thiotepa riemser ChEMBL registry synonym — accepted as the source's own label CHEMBL671
Known as Tiotepa ChEMBL registry synonym — accepted as the source's own label CHEMBL671
Known as triethylenethiophosphoramide “Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent” NCT02626715
Known as TSPA “myeloablative chemotherapy with thiotepa (TSPA) followed by carboplatin (CBDCA)” NCT00002619
2

“Thiotepa, TSPA, NSC-6396” NCT00002471

TSPA Thiotepa, NSC-6396” NCT00002704

Action Inhibit “Carboplatin and thiotepa are designed to interfere with the growth of cancer cells by stopping cell division” NCT00429182
Modality Other / unclassified “Thiotepa, a highly myeloablative bifunctional alkylating agent” NCT00607984
Route Intravenous “thiotepa IV over 3 hours” NCT00002515